Click here to get full coverage on New Analyst Forecast: $ALZN Given $28 Price Target | ALZN Stock News - Quiver Quantitative

New Analyst Forecast: $ALZN Given $28 Price Target | ALZN Stock News  Quiver Quantitative

New Analyst Forecast: $ALZN Given $28 Price Target | ALZN Stock News - Quiver Quantitative

Click here to get full coverage on Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Yahoo Finance

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?  Yahoo Finance

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Yahoo Finance

Click here to get full coverage on Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan

Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data  Stock Titan

Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan

Click here to get full coverage on Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq

Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation  Nasdaq

Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq

Click here to get full coverage on Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN) - The Globe and Mail

Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN)  The Globe and Mail

Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN) - The Globe and Mail

Click here to get full coverage on Ault Milton C III sells Alzamend Neuro (ALZN) shares for $344,222 - Investing.com

Ault Milton C III sells Alzamend Neuro (ALZN) shares for $344,222  Investing.com

Ault Milton C III sells Alzamend Neuro (ALZN) shares for $344,222 - Investing.com

Click here to get full coverage on 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session  Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Click here to get full coverage on Will ALZN stock benefit from infrastructure spending - 2025 Earnings Impact & Real-Time Chart Pattern Alerts - Улправда

Will ALZN stock benefit from infrastructure spending - 2025 Earnings Impact & Real-Time Chart Pattern Alerts  Улправда

Will ALZN stock benefit from infrastructure spending - 2025 Earnings Impact & Real-Time Chart Pattern Alerts - Улправда

Click here to get full coverage on Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update - TipRanks

Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update  TipRanks

Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update - TipRanks

Click here to get full coverage on Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - Stocktwits

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled  Stocktwits

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - Stocktwits

Click here to get full coverage on Ault Milton C III sells Alzamend Neuro (ALZN) stock for $56,696 - Investing.com

Ault Milton C III sells Alzamend Neuro (ALZN) stock for $56,696  Investing.com

Ault Milton C III sells Alzamend Neuro (ALZN) stock for $56,696 - Investing.com

Click here to get full coverage on Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?  Yahoo Finance

Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Click here to get full coverage on Novel Lithium Drug Enters Phase II Trial, Targets 43M Patients With Brain Disorders Without Blood Monitoring - Stock Titan

Novel Lithium Drug Enters Phase II Trial, Targets 43M Patients With Brain Disorders Without Blood Monitoring  Stock Titan

Novel Lithium Drug Enters Phase II Trial, Targets 43M Patients With Brain Disorders Without Blood Monitoring - Stock Titan

Click here to get full coverage on Alzamend Neuro Mourns Loss of Director Andrew Woo - The Globe and Mail

Alzamend Neuro Mourns Loss of Director Andrew Woo  The Globe and Mail

Alzamend Neuro Mourns Loss of Director Andrew Woo - The Globe and Mail

Click here to get full coverage on How ALZN stock performs in rate cut cycles - Market Risk Analysis & Fast Moving Stock Trade Plans - Улправда

How ALZN stock performs in rate cut cycles - Market Risk Analysis & Fast Moving Stock Trade Plans  Улправда

How ALZN stock performs in rate cut cycles - Market Risk Analysis & Fast Moving Stock Trade Plans - Улправда

Click here to get full coverage on Alzamend Neuro announces passing of board member Andrew H. Woo - Investing.com

Alzamend Neuro announces passing of board member Andrew H. Woo  Investing.com

Alzamend Neuro announces passing of board member Andrew H. Woo - Investing.com

Click here to get full coverage on Alzamend Neuro Announces Reverse Stock Split - Yahoo Finance

Alzamend Neuro Announces Reverse Stock Split  Yahoo Finance

Alzamend Neuro Announces Reverse Stock Split - Yahoo Finance

Click here to get full coverage on What hedge fund activity signals for ALZN stock - July 2025 PostEarnings & Free High Accuracy Swing Entry Alerts - Улправда

What hedge fund activity signals for ALZN stock - July 2025 PostEarnings & Free High Accuracy Swing Entry Alerts  Улправда

What hedge fund activity signals for ALZN stock - July 2025 PostEarnings & Free High Accuracy Swing Entry Alerts - Улправда

Click here to get full coverage on Will ALZN stock benefit from green energy trends - Breakout Watch & Fast Gain Swing Alerts - Улправда

Will ALZN stock benefit from green energy trends - Breakout Watch & Fast Gain Swing Alerts  Улправда

Will ALZN stock benefit from green energy trends - Breakout Watch & Fast Gain Swing Alerts - Улправда

Click here to get full coverage on Alzamend Neuro’s New Trials Spark Curiosity - StocksToTrade

Alzamend Neuro’s New Trials Spark Curiosity  StocksToTrade

Alzamend Neuro’s New Trials Spark Curiosity - StocksToTrade

Click here to get full coverage on Can ALZN stock attract ESG capital inflows - Weekly Trend Recap & Fast Gaining Stock Reports - Улправда

Can ALZN stock attract ESG capital inflows - Weekly Trend Recap & Fast Gaining Stock Reports  Улправда

Can ALZN stock attract ESG capital inflows - Weekly Trend Recap & Fast Gaining Stock Reports - Улправда

Click here to get full coverage on Alzamend Neuro director Ault sells $226,923 in shares - Investing.com

Alzamend Neuro director Ault sells $226,923 in shares  Investing.com

Alzamend Neuro director Ault sells $226,923 in shares - Investing.com

Click here to get full coverage on Valuation Update: Can SunOpta Inc expand its profit margins - Market Activity Report & AI Enhanced Trade Execution Alerts - baoquankhu1.vn

Valuation Update: Can SunOpta Inc expand its profit margins - Market Activity Report & AI Enhanced Trade Execution Alerts  baoquankhu1.vn

Valuation Update: Can SunOpta Inc expand its profit margins - Market Activity Report & AI Enhanced Trade Execution Alerts - baoquankhu1.vn

Click here to get full coverage on Alzamend Neuro Mourns Loss of Director Andrew Woo - TipRanks

Alzamend Neuro Mourns Loss of Director Andrew Woo  TipRanks

Alzamend Neuro Mourns Loss of Director Andrew Woo - TipRanks

Click here to get full coverage on About Us - FinancialContent

About Us - FinancialContent

Click here to get full coverage on Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares  Investing.com

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com

Click here to get full coverage on Contact - The Lethbridge Herald - News and Sports from around Lethbridge - FinancialContent

Contact - The Lethbridge Herald - News and Sports from around Lethbridge  FinancialContent

Contact - The Lethbridge Herald - News and Sports from around Lethbridge - FinancialContent

Click here to get full coverage on ALZN - Alzamend Neuro Inc Latest Stock News & Market Updates - Stock Titan

ALZN - Alzamend Neuro Inc Latest Stock News & Market Updates  Stock Titan

ALZN - Alzamend Neuro Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Daily Breeze - FinancialContent

Daily Breeze - FinancialContent

Click here to get full coverage on ALZN Stock Price and Chart — NASDAQ:ALZN - TradingView — Track All Markets

ALZN Stock Price and Chart — NASDAQ:ALZN  TradingView — Track All Markets

ALZN Stock Price and Chart — NASDAQ:ALZN - TradingView — Track All Markets

Click here to get full coverage on Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com UK

Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com  Investing.com UK

Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com UK

Click here to get full coverage on Why Alzamend Neuro Stock Popped Today - The Motley Fool

Why Alzamend Neuro Stock Popped Today  The Motley Fool

Why Alzamend Neuro Stock Popped Today - The Motley Fool

Click here to get full coverage on Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Business Wire

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital  Business Wire

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Business Wire

Click here to get full coverage on EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study - Yahoo Finance

EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study  Yahoo Finance

EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study - Yahoo Finance

Click here to get full coverage on ALZN IPO News - Preclinical Alzheimer's biotech Alzamend Neuro files for a $12 million IPO - renaissancecapital.com

ALZN IPO News - Preclinical Alzheimer's biotech Alzamend Neuro files for a $12 million IPO  renaissancecapital.com

ALZN IPO News - Preclinical Alzheimer's biotech Alzamend Neuro files for a $12 million IPO - renaissancecapital.com

Click here to get full coverage on SEC Alleges $100 Million Stock Manipulation Scheme via Social Media - Barron's

SEC Alleges $100 Million Stock Manipulation Scheme via Social Media  Barron's

SEC Alleges $100 Million Stock Manipulation Scheme via Social Media - Barron's

Click here to get full coverage on 4 Penny Stocks Making Waves: ALZN CGAC METX WDLF - Insider Financial

4 Penny Stocks Making Waves: ALZN CGAC METX WDLF  Insider Financial

4 Penny Stocks Making Waves: ALZN CGAC METX WDLF - Insider Financial

Click here to get full coverage on Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency - TipRanks

Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency  TipRanks

Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency - TipRanks

Click here to get full coverage on 4 Alzheimer’s Penny Stocks To Watch After Biogen Stock Explodes - PennyStocks.com

4 Alzheimer’s Penny Stocks To Watch After Biogen Stock Explodes  PennyStocks.com

4 Alzheimer’s Penny Stocks To Watch After Biogen Stock Explodes - PennyStocks.com

Click here to get full coverage on Precipitation phenomena in Al-Zn-Mg alloy matrix composites reinforced with B4C particles | Scientific Reports - Nature

Precipitation phenomena in Al-Zn-Mg alloy matrix composites reinforced with B4C particles | Scientific Reports  Nature

Precipitation phenomena in Al-Zn-Mg alloy matrix composites reinforced with B4C particles | Scientific Reports - Nature

Click here to get full coverage on Alzamend Neuro Stock (ALZN) Surges 30% After Positive FDA Response Regarding Alzheimer’s Vaccine - AskTraders.com

Alzamend Neuro Stock (ALZN) Surges 30% After Positive FDA Response Regarding Alzheimer’s Vaccine  AskTraders.com

Alzamend Neuro Stock (ALZN) Surges 30% After Positive FDA Response Regarding Alzheimer’s Vaccine - AskTraders.com

Click here to get full coverage on Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell? - Defense World

Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell?  Defense World

ALZN

Price Chart

Key Statistics

Technicals

About ALZN

Latest News

New Analyst Forecast: $ALZN Given $28 Price Target | ALZN Stock News - Quiver Quantitative

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Yahoo Finance

Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan

Advanced Charts

Top Gainers

Top Losers